

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Guido HENNING, et al

Serial No.: 10/022,618

Group Number:

Filed: 12/17/2001

Examiner:

For: Method for Specifically Detecting Tumor
Cells and their Precursors in Uterine
Cervical Smears by Simultaneously
Measuring at Least 2 Different Molecular
Markers

DTOS Rec'd PCT/PTO 19 DEC 2003**CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)**

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, PO. Box 1450, Alexandria, VA 22313-1450.

Date: December 17, 2003

Monica McGovern
Monica McGovern

**ASSISTANT COMMISSIONER FOR PATENTS
PO BOX 1450
ALEXANDRIA, VA 22313-1450**

**TRANSMITTAL OF SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449. These references were cited in the International Search Report (Form PCT/ISA/210) for the corresponding International Application (PCT/US02/28912).

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Susan M. Pellegrino
Susan M. Pellegrino

Attorney for Applicant(s)
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516

Reg. No. 48972

Telephone: (203) 812-6450

Date: December 17, 2003

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Serial No. 10/022,618	Group Art Unit 1645	Filing Date 12/17/2001	Atty. Docket No. LeA 35 010
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION		Applicant(s) Guid HENNING, et al			

U.S. PATENT DOCUMENTS													
*		DOCUMENT NO.							DATE MM/DD/YY	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	U1	5	9	3	2	4	1	2	08/03/99	DILLNER			

FOREIGN PATENT DOCUMENTS														
		DOCUMENT NO.							DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION	
		YES	NO											
	F1	9	9	2	1	0	1	4	29/04/99	WO				
	F2	0	0	2	4	7	6	0	04/05/00	WO				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)													
	R1	BERGERON, Human Papillomaviruses Associated with Cervical Intraepithelial Neoplasia, Am. J. Surgical Pathology, 16(7):641-649, 1992											
	R2	BUSMANIS, Biomarkers in Carcinoma of the Cervix, Emphasis on Tissue-related Factors and their Potential Prognostic Factors, Ann. Acad. Med Singapore, 1998; 27:641-5											
	R3	HANNE, Aberrant Expression of the Cell Cycle Associated Proteins TP53, MDM2, p21, p27, cdk4, Cyclin D1, RB and EGFR in Cervical Carcinomas, Gynecologic Oncology 73:223-228 (1999)											
	R4	MITRA, ERBB2 (HER2/neu) Oncogene is Frequently Amplified in Squamous Cell Carcinoma of the Uterine Cervix, Cancer Research 54:637-639, February 1, 1994											
	R5	RADHAKRISHNA, The Presence of Human Papillomavirus-16/-18 E6, p53, and Bcl-2 protein in Cervicovaginal Smears from Patients with Invasive Cervical Cancer, Cancer Epidemiology, Biomarkers & Prevention, Vol. 5, 239-335, May 1996											
	R6	KERSEMAEKERS, Oncogene Alterations in Carcinomas of the Uterine Cervix: Overexpression of the Epidermal Growth Factor Receptor is Associated with Poor Prognosis, Clinical Cancer Research, Vol. 5, 577-586, March 1999											
	R7	MUNIRAJAN, The Status of Human Papillomavirus and Tumor Suppressor Genes p53 and p16 in Carcinomas of Uterine Cervix from India, Gynecologic Oncology 69:205-209 (1998)											

EXAMINER	DATE CONSIDERED
<p>* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	